World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
71
Citations
32906
World Ranking
19923
National Ranking
9921

Overview

Stanley Cohen is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research focuses primarily on the field of Medicine, with extensive contributions to Rheumatology, Immunology, Hematology, Genetics, and Pathology and Forensic Medicine.

The scientist has published notably in several high-impact venues, including:

  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Rheumatology and Therapy
  • RMD Open
  • Lara D. Veeken

Cohen's scholarly work centers around topics such as Rheumatoid Arthritis Research and Therapies, Biosimilars and Bioanalytical Methods, Autoimmune and Inflammatory Disorders Research, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, and Pharmaceutical studies and practices.

Recent publications authored or co-authored by Stanley Cohen include:

  • Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme, 2020, Annals of the Rheumatic Diseases

Other relevant recent papers from the same research community include:

  • American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3, 2020, Arthritis & Rheumatology
  • Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data, 2020, Annals of the Rheumatic Diseases
  • American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1, 2020, Arthritis & Rheumatology
  • Oral surveillance and JAK inhibitor safety: the theory of relativity, 2022, Nature Reviews Rheumatology

Frequent collaborators include researchers such as Gerd R Burmester, Yoshiya Tanaka, Kevin Winthrop, Jeffrey R. Curtis, and Eduardo Mysler, indicating ongoing partnerships within the rheumatologic and immunologic research communities.

Best Publications

  • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Ferdinand C Breedveld;Michael H Weisman;Arthur F Kavanaugh;Stanley B Cohen

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

    Larry W. Moreland;Scott W. Baumgartner;Michael H. Schiff;Elizabeth A. Tindall

  • Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

    Philip J. Mease;Alan J. Kivitz;Francis X. Burch;Evan L. Siegel

  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

    Ronald F. van Vollenhoven;Roy Fleischmann;Stanley Cohen;Eun Bong Lee

  • Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate

    Vibeke Strand;Stanley Cohen;Michael Schiff;Arthur Weaver

  • Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

    Stanley Cohen;Eric Hurd;John Cush;Michael Schiff

  • Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

    Stanley B. Cohen;Robin K. Dore;Nancy E. Lane;Peter A. Ory

  • Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Stanley Cohen;Robert M. Levy;Michael Keller;Eugene Boling

  • Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

    Mark C. Genovese;Stanley Cohen;Larry Moreland;Deborah Lium

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.

    Clifton O. Bingham;J. Chris Buckland-Wright;Patrick Garnero;Stanley B. Cohen

  • Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

    Larry W. Moreland;Rieke Alten;Filip Van Den Bosch;Thierry Appelboom

  • A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

    Joel M. Kremer;Stanley Cohen;Bethanie E. Wilkinson;Carol A. Connell

  • Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

    E Michael Lewiecki;Paul D Miller;Michael R McClung;Stanley B Cohen

  • Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

    Stanley B. Cohen;Yoshiya Tanaka;Xavier Mariette;Jeffrey R. Curtis

  • Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate

    Stanley Cohen;Grant W. Cannon;Michael Schiff;Arthur Weaver

  • A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

    S B Cohen;L W Moreland;J J Cush;M W Greenwald

  • A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.

    Dianne Petrone;John J. Condemi;Rose Fife;Oscar Gluck

  • Cytokine function: a study in biologic diversity.

    Marion C. Cohen;Stanley Cohen

Frequent Co-Authors

Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Paul Emery
Paul Emery University of Leeds
Yoshiya Tanaka
Yoshiya Tanaka University of Occupational and Environmental Health Japan
Mark C. Genovese
Mark C. Genovese Stanford University
Alan J. Kivitz
Alan J. Kivitz Altoona Arthritis and Osteoporosis Center
Edward C. Keystone
Edward C. Keystone University of Toronto
Joel M. Kremer
Joel M. Kremer Albany Medical Center Hospital
Vibeke Strand
Vibeke Strand Stanford University
Larry W. Moreland
Larry W. Moreland University of Colorado Anschutz Medical Campus
Jeffrey R. Curtis
Jeffrey R. Curtis University of Alabama at Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t mean following a single, traditional path. Today, many students are pursuing related online degrees that lead to rewarding roles in healthcare. Online programs offer flexibility and accessibility – letting you balance study with other life commitments.

If you want a fast track into nursing, consider absn programs that don't require teas. These programs allow eligible students to earn their Bachelor of Science in Nursing without additional exams, making it easier and more efficient to move into the nursing profession.

Interested in healthcare leadership? Pursue a healthcare administration online degree to prepare for management roles in hospitals, clinics, or public health organizations. Registered nurses can also advance their practice through rn to fnp bridge programs, which allow nursing professionals to become Family Nurse Practitioners in less time.

Nutrition is another essential part of the medical field. With the best online nutrition degree programs, you can work toward credentials for counseling, education, or research in nutrition and dietetics.

Best Scientists Citing Stanley Cohen

Trending Scientists